Starting Wegovy 1.5 mg: what the third dose step is really for

Picture yourself four weeks into 0.5 mg, pen in hand, wondering what comes next

You've made it through the 0.25 mg starter and a month at 0.5 mg. The nausea that crept in after the first couple of injections has mostly quietened. You might have noticed your appetite shifting a little, meals feeling satisfying sooner. That subtle change is semaglutide beginning to work on the GLP-1 receptors involved in appetite signalling and gastric emptying.

Now the schedule moves to 1.5 mg, and the purpose here is less dramatic than it sounds. The Wegovy dosing schedule is built around protecting you from side effects rather than rushing to results. Each step gives your digestive system another month to adapt before the concentration increases again. At 1.5 mg you are still in preparatory territory. Most clinical attention at this stage is on tolerability: is your body settling in, are you staying hydrated, is anything flagging that warrants a slower pace?

One practical check worth doing every week: before you inject, confirm the liquid in the pen window is clear and colourless, with no particles. It takes ten seconds and is a straightforward habit recommended in Wegovy's patient information leaflet. Store the pen in the fridge between 2°C and 8°C; consult the leaflet for the precise guidance on room-temperature limits if you're travelling.

What the titration schedule actually looks like at the 1.5 mg stage

Wegovy's standard route runs 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and then 2.4 mg as the established maintenance dose, each held for approximately four weeks. The 1.5 mg step doesn't appear in the original schedule by that number (the third step is labelled 1.0 mg) which causes real confusion for people looking up "Wegovy 1 mg" versus "Wegovy 1.5 mg".

The 1.5 mg dose entered the picture with the approval of the higher-dose 7.2 mg pathway. The full Wegovy strength range now spans several dose steps, and for some patients the route to 7.2 mg moves through a 1.5 mg increment. Your prescriber will specify which ladder applies to you based on how you've responded and what the clinical goal is.

If you're on the standard 2.4 mg pathway, your third month is likely 1.0 mg, not 1.5 mg. If you're seeing 1.5 mg on your prescription, it's worth confirming with your prescriber which route you're on. That clarity matters because the 1.0 mg step and the 1.5 mg step are distinct, even if the difference looks small.

For context on where 1.5 mg sits relative to the higher steps, the 2 mg dose page explains how the later steps are structured. The NHS medicines page for semaglutide sets out the general titration framework in plain language and is a reliable reference alongside your Patient Information Leaflet.

Side effects at 1.5 mg and how they tend to behave

The pattern at 1.5 mg follows what you'll have seen at earlier steps: gastrointestinal symptoms are the most commonly reported. Nausea tends to be the headline complaint, often peaking in the days after the injection and easing towards the end of the week. Indigestion, looser stools, constipation or a general queasiness can all appear. Fatigue after injecting isn't unusual either.

A dose step-up is when these effects are most likely to resurface, even if 0.5 mg felt comfortable. That's expected, a higher concentration means more GLP-1 receptor activation, which slows gastric emptying further and can renew symptoms that had calmed down. They typically settle within one to two weeks of staying at the same dose.

The NHS's semaglutide patient information lists common and uncommon side effects in full. Anything that doesn't follow that transient pattern (particularly severe or persistent abdominal pain that spreads to your back, with or without vomiting) warrants prompt medical attention, as the MHRA has highlighted acute pancreatitis as a known, albeit infrequent, serious side effect of GLP-1 medicines. Report any suspected adverse reactions through the MHRA's Yellow Card scheme.

Missed-dose decisions at any stage of titration are worth reading about carefully. Guidance on what to do if you miss an injection explains the time windows that determine your options, it isn't one-size-fits-all.

Whether 1.5 mg is where your treatment should be right now is a clinical conversation

Some people tolerate titration smoothly and move through each step without incident. Others need an extra month at a given dose. A smaller number find a particular step persistently uncomfortable and discuss staying put or adjusting the pace with their prescriber.

None of those outcomes is a failure. The titration schedule exists precisely because individual responses to semaglutide vary. Weight loss at these preparatory doses is typically modest compared to what happens at maintenance, that's normal, and expected.

If you're weighing up the full Wegovy treatment picture or thinking about starting from scratch and want to understand all the steps before committing, an overview of the weight-loss treatments we support is a good starting point. When you're ready to speak with someone clinical about your specific situation (current dose, how you're tolerating it, or whether Wegovy is the right fit at all) you can start a free consultation with our prescribers, who review every case personally.